Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Total Non-Current Liabilities (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Total Non-Current Liabilities data on record, last reported at $548.4 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 4.88% year-over-year to $548.4 million; the TTM value through Dec 2025 reached $548.4 million, down 4.88%, while the annual FY2025 figure was $548.4 million, 4.88% down from the prior year.
  • Total Non-Current Liabilities reached $548.4 million in Q4 2025 per CAI's latest filing, up from $506.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $576.5 million in Q4 2024 and bottomed at -$491.3 million in Q2 2025.